A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

To join this study, you must have advanced non-small cell lung cancer that has spread or cannot be cured with surgery. Your cancer must also have a specific genetic change (an EGFR mutation, either Ex19del or L858R) that has been found by a special test.

You also need to be generally well enough to take part, meaning you can mostly look after yourself. Any side effects from previous cancer treatments should have mostly cleared up, with only minor issues remaining. The doctors will also need to be able to measure at least one of your cancer spots on scans.

There are some reasons why you might not be able to join. For example, if you have certain lung conditions like scarring or inflammation (interstitial lung disease or radiation pneumonitis), or if you've had major surgery recently or have one planned. The study doctors will carefully review your medical history to make sure it's safe for you to participate.

Taking part in this study means you would receive one of the experimental treatments mentioned (either amivantamab plus lazertinib, or amivantamab plus chemotherapy). You would have regular appointments to see the study doctors and nurses. During these visits, you'll have physical exams, blood tests, and scans (like CT scans) to see how the treatment is working and check for any side effects. You'll also be asked about how you are feeling and any symptoms you might have. The exact number of visits and tests will depend on the phase of the study and how long you are on treatment. You will continue treatment and follow-up as long as the treatment is helping and you are tolerating it well. The total duration of your participation could vary greatly depending on your individual response to the treatment.